21st Century Cell Culture for 21st Century Toxicology.

There is no good science in bad models. Cell culture is especially prone to artifacts. A number of novel cell culture technologies have become more broadly available in the 21st century, which allow overcoming limitations of traditional culture and are more physiologically relevant. These include the use of stem-cell derived human cells, cocultures of different cell types, scaffolds and extracellular matrices, perfusion platforms (such as microfluidics), 3D culture, organ-on-chip technologies, tissue architecture, and organ functionality. The physiological relevance of such models is further enhanced by the measurement of biomarkers (e.g., key events of pathways), organ specific functionality, and more comprehensive assessment cell responses by high-content methods. These approaches are still rarely combined to create microphysiological systems. The complexity of the combination of these technologies can generate results closer to the in vivo situation but increases the number of parameters to control, bringing some new challenges. In fact, we do not argue that all cell culture needs to be that sophisticated. The efforts taken are determined by the purpose of our experiments and tests. If only a very specific molecular target to cell response is of interest, a very simple model, which reflects this, might be much more suited to allow standardization and high-throughput. However, the less defined the end point of interest and cellular response are, the better we should approximate organ- or tissue-like culture conditions to make physiological responses more probable. Besides these technologic advances, important progress in the quality assurance and reporting on cell cultures as well as the validation of cellular test systems brings the utility of cell cultures to a new level. The advancement and broader implementation of Good Cell Culture Practice (GCCP) is key here. In toxicology, this is a major prerequisite for meaningful and reliable results, ultimately supporting risk assessment and product development decisions.

[1]  Tanja Waldmann,et al.  Rapid, complete and large‐scale generation of post‐mitotic neurons from the human LUHMES cell line , 2011, Journal of neurochemistry.

[2]  Marcel Leist,et al.  Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. , 2010, ALTEX.

[3]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[4]  J. Qin,et al.  Genetic profiling reveals an alarming rate of cross‐contamination among human cell lines used in China , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Katie Lidster,et al.  Two Years Later: Journals Are Not Yet Enforcing the ARRIVE Guidelines on Reporting Standards for Pre-Clinical Animal Studies , 2014, PLoS biology.

[6]  Annette Kopp-Schneider,et al.  Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  Stephan Aiche,et al.  Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[8]  Ewelina Tomecka,et al.  Heart-on-a-chip based on stem cell biology. , 2016, Biosensors & bioelectronics.

[9]  Melvin E Andersen,et al.  Developing microphysiological systems for use as regulatory tools--challenges and opportunities. , 2014, ALTEX.

[10]  Brigitte Schlegelberger,et al.  Genetic instability of modified stem cells - a first step towards malignant transformation? , 2013, American journal of stem cells.

[11]  M. Heinemann,et al.  Detection of contaminants in cell cultures, sera and trypsin. , 2013, Biologicals : journal of the International Association of Biological Standardization.

[12]  Melvin E. Andersen,et al.  Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function , 2016, Scientific Reports.

[13]  Madeline A. Lancaster,et al.  Cerebral organoids model human brain development and microcephaly , 2013, Nature.

[14]  Vivien Marx,et al.  Cell-line authentication demystified , 2014, Nature Methods.

[15]  Thomas Hartung,et al.  Food for thought... on cell culture. , 2007, ALTEX.

[16]  Valérie Zuang,et al.  A Modular Approach to the ECVAM Principles on Test Validity , 2004, Alternatives to laboratory animals : ATLA.

[17]  D. Debanne,et al.  Organotypic slice cultures: a technique has come of age , 1997, Trends in Neurosciences.

[18]  Thomas Hartung,et al.  A Toxicology for the 21st Century—Mapping the Road Ahead , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  T. Hartung Toxicology for the twenty-first century , 2009, Nature.

[20]  David M. Reif,et al.  Toxicity Testing in the 21st Century Beyond Environmental Chemicals , 2018, ALTEX.

[21]  Scott H Randell,et al.  Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. , 2008, Proceedings of the American Thoracic Society.

[22]  Paul Jennings,et al.  Comprehensive summary--Predict-IV: A systems toxicology approach to improve pharmaceutical drug safety testing. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[23]  H. Drexler,et al.  Mix-ups and mycoplasma: the enemies within. , 2002, Leukemia research.

[24]  R. Lahesmaa,et al.  Genetic and epigenetic stability of human pluripotent stem cells , 2012, Nature Reviews Genetics.

[25]  Yu Huang,et al.  Brain slice on a chip: opportunities and challenges of applying microfluidic technology to intact tissues. , 2012, Lab on a chip.

[26]  Mardas Daneshian,et al.  Animal use for science in Europe. , 2015, ALTEX.

[27]  T. Chen,et al.  Mycoplasma infection of cultured cells , 1989, Nature.

[28]  Michael Balls,et al.  Guidance on Good Cell Culture Practice , 2005, Alternatives to laboratory animals : ATLA.

[29]  Paul Jennings,et al.  Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 1: technical description. , 2004, ALTEX.

[30]  Stephen A Boppart,et al.  Imaging and analysis of three-dimensional cell culture models. , 2010, Methods in molecular biology.

[31]  A. Vickers,et al.  Preparation and culture of precision-cut organ slices from human and animal , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  Jerry C. Hu,et al.  Advances in tissue engineering through stem cell‐based co‐culture , 2015, Journal of tissue engineering and regenerative medicine.

[33]  T Hartung,et al.  Endotoxin-inducible cytotoxicity in liver cell cultures--I. , 1991, Biochemical pharmacology.

[34]  Martin Fussenegger,et al.  Microscale tissue engineering using gravity-enforced cell assembly. , 2004, Trends in biotechnology.

[35]  M. Baker 1,500 scientists lift the lid on reproducibility , 2016, Nature.

[36]  T. Hartung Food for thought ... on validation. , 2007, ALTEX.

[37]  L. Gribaldo,et al.  High variability of genomic instability and gene expression profiling in different HeLa clones , 2015, Scientific Reports.

[38]  H. Drexler,et al.  Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention , 2002, Cytotechnology.

[39]  Gian Paolo Rossini,et al.  Towards tailored assays for cell-based approaches to toxicity testing. , 2012, ALTEX.

[40]  Thomas Hartung,et al.  Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. , 2012, ALTEX.

[41]  Anton Simeonov,et al.  Good Cell Culture Practice for stem cells and stem-cell-derived models. , 2016, ALTEX.

[42]  J. Collins,et al.  Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip , 2015, Proceedings of the National Academy of Sciences.

[43]  Ali Khademhosseini,et al.  From cardiac tissue engineering to heart-on-a-chip: beating challenges , 2015, Biomedical materials.

[44]  Andrew Worth,et al.  Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.

[45]  Michael Balls,et al.  ECVAM Good Cell Culture Practice Task Force Report 1 , 2002, Alternatives to laboratory animals : ATLA.

[46]  Thomas Hartung,et al.  3D - a new dimension of in vitro research. , 2014, Advanced drug delivery reviews.

[47]  Thomas Hartung,et al.  Toward a 3D model of human brain development for studying gene/environment interactions , 2013, Stem Cell Research & Therapy.

[48]  R. McKay,et al.  Consensus Guidance for Banking and Supply of Human Embryonic Stem Cell Lines for Research Purposes , 2009, Stem Cell Reviews and Reports.

[49]  T. Hartung Look back in anger - what clinical studies tell us about preclinical work. , 2013, ALTEX.

[50]  Rui L Reis,et al.  Towards the design of 3D multiscale instructive tissue engineering constructs: Current approaches and trends. , 2015, Biotechnology advances.

[51]  Elmar Willbold,et al.  Of layers and spheres: the reaggregate approach in tissue engineering , 2002, Trends in Neurosciences.

[52]  J. Haycock,et al.  State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. , 2008 .

[53]  Paul Jennings,et al.  "The future of in vitro toxicology". , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[54]  Alison P McGuigan,et al.  Micropatterning strategies to engineer controlled cell and tissue architecture in vitro. , 2015, BioTechniques.

[55]  Shayn E Armstrong,et al.  The scope of mycoplasma contamination within the biopharmaceutical industry. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[56]  Thomas Hartung,et al.  The dawning of a new age of toxicology. , 2008, ALTEX.

[57]  T Hartung,et al.  Endotoxin-inducible cytotoxicity in liver cell cultures--II. Demonstration of endotoxin-tolerance. , 1992, Biochemical pharmacology.

[58]  Steven L. Stice,et al.  Preserving the genetic integrity of human embryonic stem cells , 2005, Nature Biotechnology.

[59]  Paul Jennings,et al.  Stem cell-derived systems in toxicology assessment. , 2015, Stem cells and development.

[60]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[61]  A. J. Gandolfi,et al.  Precision-cut tissue slices: applications in pharmacology and toxicology. , 1995, Life sciences.

[62]  Thomas Hartung,et al.  Pathways of Toxicity. , 2014, ALTEX.

[63]  M. Ritskes-Hoitinga,et al.  A Gold Standard Publication Checklist to Improve the Quality of Animal Studies, to Fully Integrate the Three Rs, and to Make Systematic Reviews More Feasible , 2010, Alternatives to laboratory animals : ATLA.

[64]  Uwe Marx,et al.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. , 2016, ALTEX.

[65]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[66]  Thomas Hartung,et al.  Food for thought ... on the evolution of toxicology and the phasing out of animal testing. , 2008, ALTEX.

[67]  G. Whitesides The origins and the future of microfluidics , 2006, Nature.

[68]  Ashok Kumar,et al.  Semi-automated relative quantification of cell culture contamination with mycoplasma by Photoshop-based image analysis on immunofluorescence preparations. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[69]  Thomas Hartung,et al.  Food for thought... on the economics of animal testing. , 2009, ALTEX.

[70]  Paul Jennings,et al.  Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 2: toxicological evaluation. , 2004, ALTEX.

[71]  Uwe Marx,et al.  ‘Human-on-a-chip’ Developments: A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man? , 2012, Alternatives to laboratory animals : ATLA.